Form 6-K REGENTIS BIOMATERIALS For: Oct 13

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of October 2026

 

Commission file number: 001-42834

 

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

 

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

CONTENTS

 

On October 12, 2026, Regentis Biomaterials Ltd. issued a press release entitled “Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC® at 8th ICRS Summit in Portugal.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release dated October 12, 2026.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Regentis Biomaterials Ltd.
Date: October 13, 2026	By:	/s/ Ori Gon
	Name:	Ori Gon
	Title:	Chief Financial Officer

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE DATED OCTOBER 12, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bitcoin News: Strategy’s MSCI Eligibility Comes Under Pressure as Remittix Approaches Its November Market Debut
• CGTN: From 'potato capital' to 'token city': How a city in north China is transforming
• Secure Mark USA Makes Federal Trademark Filing More Accessible for American Entrepreneurs and Small Businesses